Amryt, the Dublin-based rare drug developer, is in talks with medicines regulators in Britain and other European countries to get its treatments approved for payment reimbursement.
Britain is one of the remaining large European markets where metreleptin, a treatment for lipodystrophy, is yet to be approved for payment following its launch last year. The medical condition involves an abnormal distribution of fat in the body.
Joe Wiley, Amryt's chief executive, said last week that it...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Team Pass
Get a Business Account for you and your team